APO Research
Talk to an analyst

APO RESEARCH · REPORT

Axial Spondyloarthritis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Axial Spondyloarthritis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025187 pages

Choose your research edition.

Industry ResearchAxial Spondyloarthritis Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Axial Spondyloarthritis Drugs Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Axial Spondyloarthritis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Axial Spondyloarthritis Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Axial Spondyloarthritis Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Axial Spondyloarthritis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Axial Spondyloarthritis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Axial Spondyloarthritis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Axial Spondyloarthritis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Axial Spondyloarthritis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Axial Spondyloarthritis Drugs include Johnson & Johnson, Novartis AG, Eli Lilly and Company, AstraZeneca Plc, UCB SA, Sun Pharma Advanced Research Company Ltd, Sandoz International GmbH and Panacea Biotec Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Axial Spondyloarthritis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Axial Spondyloarthritis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Axial Spondyloarthritis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Axial Spondyloarthritis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Axial Spondyloarthritis Drugs Segment by Company

Johnson & Johnson

Novartis AG

Eli Lilly and Company

AstraZeneca Plc

UCB SA

Sun Pharma Advanced Research Company Ltd

Sandoz International GmbH

Panacea Biotec Ltd

Axial Spondyloarthritis Drugs Segment by Type

Ixekizumab

Secukinumab

Certolizumab Pegol

Etanercept Biosimilar

Others

Axial Spondyloarthritis Drugs Segment by Application

Clinic

Hospital

Home Care

Axial Spondyloarthritis Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Axial Spondyloarthritis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Axial Spondyloarthritis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Axial Spondyloarthritis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Axial Spondyloarthritis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Axial Spondyloarthritis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Axial Spondyloarthritis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Axial Spondyloarthritis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Axial Spondyloarthritis Drugs Industry Trends Table 2. Axial Spondyloarthritis Drugs Industry Drivers Table 3. Axial Spondyloarthritis Drugs Industry Opportunities and Challenges Table 4. Axial Spondyloarthritis Drugs Industry Restraints Table 5. Global Axial Spondyloarthritis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Axial Spondyloarthritis Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Axial Spondyloarthritis Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Axial Spondyloarthritis Drugs Sales Market Share by Manufacturers Table 9. Global Axial Spondyloarthritis Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Axial Spondyloarthritis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Axial Spondyloarthritis Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Axial Spondyloarthritis Drugs Manufacturers, Product Type & Application Table 13. Global Axial Spondyloarthritis Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Axial Spondyloarthritis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ixekizumab Table 17. Major Manufacturers of Secukinumab Table 18. Major Manufacturers of Certolizumab Pegol Table 19. Major Manufacturers of Etanercept Biosimilar Table 20. Major Manufacturers of Others Table 21. Global Axial Spondyloarthritis Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Axial Spondyloarthritis Drugs Sales by Type (2021-2026) & (K Units) Table 23. Global Axial Spondyloarthritis Drugs Sales by Type (2027-2032) & (K Units) Table 24. Global Axial Spondyloarthritis Drugs Sales Market Share by Type (2021-2026) Table 25. Global Axial Spondyloarthritis Drugs Sales Market Share by Type (2027-2032) Table 26. Global Axial Spondyloarthritis Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Axial Spondyloarthritis Drugs Revenue by Type (2021-2026) & (K Units) Table 28. Global Axial Spondyloarthritis Drugs Revenue by Type (2027-2032) & (K Units) Table 29. Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Home Care Table 34. Global Axial Spondyloarthritis Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Axial Spondyloarthritis Drugs Sales by Application (2021-2026) & (K Units) Table 36. Global Axial Spondyloarthritis Drugs Sales by Application (2027-2032) & (K Units) Table 37. Global Axial Spondyloarthritis Drugs Sales Market Share by Application (2021-2026) Table 38. Global Axial Spondyloarthritis Drugs Sales Market Share by Application (2027-2032) Table 39. Global Axial Spondyloarthritis Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Axial Spondyloarthritis Drugs Revenue by Application (2021-2026) & (K Units) Table 41. Global Axial Spondyloarthritis Drugs Revenue by Application (2027-2032) & (K Units) Table 42. Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2021-2026) Table 43. Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2027-2032) Table 44. Global Axial Spondyloarthritis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Axial Spondyloarthritis Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Axial Spondyloarthritis Drugs Sales Market Share by Region (2021-2026) Table 47. Global Axial Spondyloarthritis Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Axial Spondyloarthritis Drugs Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Axial Spondyloarthritis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Axial Spondyloarthritis Drugs Sales by Country (2021-2026) & (K Units) Table 51. North America Axial Spondyloarthritis Drugs Sales by Country (2027-2032) & (K Units) Table 52. Europe Axial Spondyloarthritis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Axial Spondyloarthritis Drugs Sales by Country (2021-2026) & (K Units) Table 54. Europe Axial Spondyloarthritis Drugs Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Axial Spondyloarthritis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Axial Spondyloarthritis Drugs Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Axial Spondyloarthritis Drugs Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Axial Spondyloarthritis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Axial Spondyloarthritis Drugs Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Axial Spondyloarthritis Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Axial Spondyloarthritis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Axial Spondyloarthritis Drugs Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Axial Spondyloarthritis Drugs Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Axial Spondyloarthritis Drugs Revenue Market Share by Region (2021-2026) Table 65. Global Axial Spondyloarthritis Drugs Revenue Market Share by Region (2027-2032) Table 66. Johnson & Johnson Company Information Table 67. Johnson & Johnson Business Overview Table 68. Johnson & Johnson Axial Spondyloarthritis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Johnson & Johnson Axial Spondyloarthritis Drugs Product Portfolio Table 70. Johnson & Johnson Recent Development Table 71. Novartis AG Company Information Table 72. Novartis AG Business Overview Table 73. Novartis AG Axial Spondyloarthritis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Novartis AG Axial Spondyloarthritis Drugs Product Portfolio Table 75. Novartis AG Recent Development Table 76. Eli Lilly and Company Company Information Table 77. Eli Lilly and Company Business Overview Table 78. Eli Lilly and Company Axial Spondyloarthritis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Eli Lilly and Company Axial Spondyloarthritis Drugs Product Portfolio Table 80. Eli Lilly and Company Recent Development Table 81. AstraZeneca Plc Company Information Table 82. AstraZeneca Plc Business Overview Table 83. AstraZeneca Plc Axial Spondyloarthritis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. AstraZeneca Plc Axial Spondyloarthritis Drugs Product Portfolio Table 85. AstraZeneca Plc Recent Development Table 86. UCB SA Company Information Table 87. UCB SA Business Overview Table 88. UCB SA Axial Spondyloarthritis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. UCB SA Axial Spondyloarthritis Drugs Product Portfolio Table 90. UCB SA Recent Development Table 91. Sun Pharma Advanced Research Company Ltd Company Information Table 92. Sun Pharma Advanced Research Company Ltd Business Overview Table 93. Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Product Portfolio Table 95. Sun Pharma Advanced Research Company Ltd Recent Development Table 96. Sandoz International GmbH Company Information Table 97. Sandoz International GmbH Business Overview Table 98. Sandoz International GmbH Axial Spondyloarthritis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Sandoz International GmbH Axial Spondyloarthritis Drugs Product Portfolio Table 100. Sandoz International GmbH Recent Development Table 101. Panacea Biotec Ltd Company Information Table 102. Panacea Biotec Ltd Business Overview Table 103. Panacea Biotec Ltd Axial Spondyloarthritis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Panacea Biotec Ltd Axial Spondyloarthritis Drugs Product Portfolio Table 105. Panacea Biotec Ltd Recent Development Table 106. Key Raw Materials Table 107. Raw Materials Key Suppliers Table 108. Axial Spondyloarthritis Drugs Distributors List Table 109. Axial Spondyloarthritis Drugs Customers List Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Axial Spondyloarthritis Drugs Product Image Figure 2. Global Axial Spondyloarthritis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Axial Spondyloarthritis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Axial Spondyloarthritis Drugs Sales (2021-2032) & (K Units) Figure 5. Global Axial Spondyloarthritis Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Axial Spondyloarthritis Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ixekizumab Image Figure 9. Secukinumab Image Figure 10. Certolizumab Pegol Image Figure 11. Etanercept Biosimilar Image Figure 12. Others Image Figure 13. Global Axial Spondyloarthritis Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Axial Spondyloarthritis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Axial Spondyloarthritis Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Axial Spondyloarthritis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Axial Spondyloarthritis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Home Care Image Figure 22. Global Axial Spondyloarthritis Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Axial Spondyloarthritis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Axial Spondyloarthritis Drugs Sales Market Share by Application (2021-2032) Figure 25. Global Axial Spondyloarthritis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Axial Spondyloarthritis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Axial Spondyloarthritis Drugs Sales Market Share by Country (2021-2032) Figure 30. U.S. Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Axial Spondyloarthritis Drugs Sales Market Share by Country (2021-2032) Figure 35. Germany Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Axial Spondyloarthritis Drugs Sales Market Share by Country (2021-2032) Figure 42. China Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Axial Spondyloarthritis Drugs Sales Market Share by Country (2021-2032) Figure 50. Brazil Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Axial Spondyloarthritis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Axial Spondyloarthritis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Axial Spondyloarthritis Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Axial Spondyloarthritis Drugs Revenue (2021-2032) & (US$ Million) Figure 61. North America Axial Spondyloarthritis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Axial Spondyloarthritis Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Europe Axial Spondyloarthritis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Axial Spondyloarthritis Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Axial Spondyloarthritis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Axial Spondyloarthritis Drugs Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Axial Spondyloarthritis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Axial Spondyloarthritis Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Axial Spondyloarthritis Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Ixekizumab
  • Secukinumab
  • Certolizumab Pegol
  • Etanercept Biosimilar
  • Others
Applications
  • Clinic
  • Hospital
  • Home Care
Companies covered
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca Plc
  • UCB SA
  • Sun Pharma Advanced Research Company Ltd
  • Sandoz International GmbH
  • Panacea Biotec Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Axial Spondyloarthritis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Axial Spondyloarthritis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Axial Spondyloarthritis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Axial Spondyloarthritis Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Axial Spondyloarthritis Drugs Market Dynamics
  1. 2.1 Axial Spondyloarthritis Drugs Industry Trends
  2. 2.2 Axial Spondyloarthritis Drugs Industry Drivers
  3. 2.3 Axial Spondyloarthritis Drugs Industry Opportunities and Challenges
  4. 2.4 Axial Spondyloarthritis Drugs Industry Restraints
3 Axial Spondyloarthritis Drugs Market by Manufacturers
  1. 3.1 Global Axial Spondyloarthritis Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Axial Spondyloarthritis Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Axial Spondyloarthritis Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Axial Spondyloarthritis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Axial Spondyloarthritis Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Axial Spondyloarthritis Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Axial Spondyloarthritis Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Axial Spondyloarthritis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Axial Spondyloarthritis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Axial Spondyloarthritis Drugs Tier 1, Tier 2, and Tier 3
4 Axial Spondyloarthritis Drugs Market by Type
  1. 4.1 Axial Spondyloarthritis Drugs Type Introduction
  2. 4.1.1 Ixekizumab
  3. 4.1.2 Secukinumab
  4. 4.1.3 Certolizumab Pegol
  5. 4.1.4 Etanercept Biosimilar
  6. 4.1.5 Others
  7. 4.2 Global Axial Spondyloarthritis Drugs Sales by Type
  8. 4.2.1 Global Axial Spondyloarthritis Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Axial Spondyloarthritis Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Axial Spondyloarthritis Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Axial Spondyloarthritis Drugs Revenue by Type
  12. 4.3.1 Global Axial Spondyloarthritis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Axial Spondyloarthritis Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2021-2032)
5 Axial Spondyloarthritis Drugs Market by Application
  1. 5.1 Axial Spondyloarthritis Drugs Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Home Care
  5. 5.2 Global Axial Spondyloarthritis Drugs Sales by Application
  6. 5.2.1 Global Axial Spondyloarthritis Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Axial Spondyloarthritis Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Axial Spondyloarthritis Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Axial Spondyloarthritis Drugs Revenue by Application
  10. 5.3.1 Global Axial Spondyloarthritis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Axial Spondyloarthritis Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2021-2032)
6 Global Axial Spondyloarthritis Drugs Sales by Region
  1. 6.1 Global Axial Spondyloarthritis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Axial Spondyloarthritis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Axial Spondyloarthritis Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Axial Spondyloarthritis Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Axial Spondyloarthritis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Axial Spondyloarthritis Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Axial Spondyloarthritis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Axial Spondyloarthritis Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Axial Spondyloarthritis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Axial Spondyloarthritis Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Axial Spondyloarthritis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Axial Spondyloarthritis Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Axial Spondyloarthritis Drugs Revenue by Region
  1. 7.1 Global Axial Spondyloarthritis Drugs Revenue by Region
  2. 7.1.1 Global Axial Spondyloarthritis Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Axial Spondyloarthritis Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Axial Spondyloarthritis Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Axial Spondyloarthritis Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Axial Spondyloarthritis Drugs Revenue (2021-2032)
  8. 7.2.2 North America Axial Spondyloarthritis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Axial Spondyloarthritis Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Axial Spondyloarthritis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Axial Spondyloarthritis Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Axial Spondyloarthritis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Axial Spondyloarthritis Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Axial Spondyloarthritis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Axial Spondyloarthritis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Axial Spondyloarthritis Drugs Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Axial Spondyloarthritis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Axial Spondyloarthritis Drugs Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Eli Lilly and Company
  14. 8.3.1 Eli Lilly and Company Company Information
  15. 8.3.2 Eli Lilly and Company Business Overview
  16. 8.3.3 Eli Lilly and Company Axial Spondyloarthritis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Company Axial Spondyloarthritis Drugs Product Portfolio
  18. 8.3.5 Eli Lilly and Company Recent Developments
  19. 8.4 AstraZeneca Plc
  20. 8.4.1 AstraZeneca Plc Company Information
  21. 8.4.2 AstraZeneca Plc Business Overview
  22. 8.4.3 AstraZeneca Plc Axial Spondyloarthritis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Plc Axial Spondyloarthritis Drugs Product Portfolio
  24. 8.4.5 AstraZeneca Plc Recent Developments
  25. 8.5 UCB SA
  26. 8.5.1 UCB SA Company Information
  27. 8.5.2 UCB SA Business Overview
  28. 8.5.3 UCB SA Axial Spondyloarthritis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 UCB SA Axial Spondyloarthritis Drugs Product Portfolio
  30. 8.5.5 UCB SA Recent Developments
  31. 8.6 Sun Pharma Advanced Research Company Ltd
  32. 8.6.1 Sun Pharma Advanced Research Company Ltd Company Information
  33. 8.6.2 Sun Pharma Advanced Research Company Ltd Business Overview
  34. 8.6.3 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Product Portfolio
  36. 8.6.5 Sun Pharma Advanced Research Company Ltd Recent Developments
  37. 8.7 Sandoz International GmbH
  38. 8.7.1 Sandoz International GmbH Company Information
  39. 8.7.2 Sandoz International GmbH Business Overview
  40. 8.7.3 Sandoz International GmbH Axial Spondyloarthritis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sandoz International GmbH Axial Spondyloarthritis Drugs Product Portfolio
  42. 8.7.5 Sandoz International GmbH Recent Developments
  43. 8.8 Panacea Biotec Ltd
  44. 8.8.1 Panacea Biotec Ltd Company Information
  45. 8.8.2 Panacea Biotec Ltd Business Overview
  46. 8.8.3 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Product Portfolio
  48. 8.8.5 Panacea Biotec Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Axial Spondyloarthritis Drugs Value Chain Analysis
  2. 9.1.1 Axial Spondyloarthritis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Axial Spondyloarthritis Drugs Production Mode & Process
  6. 9.2 Axial Spondyloarthritis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Axial Spondyloarthritis Drugs Distributors
  9. 9.2.3 Axial Spondyloarthritis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst